Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $175.00 for the company and are anticipating that the company will post $0.76 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 171 out of 265 based on the ratings given to its competitors.
MLAB has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research report on Friday, November 10th. TheStreet raised shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research report on Monday, November 6th. Finally, BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th.
Mesa Laboratories (NASDAQ MLAB) traded down $1.54 during trading on Thursday, hitting $135.10. 16,258 shares of the stock were exchanged, compared to its average volume of 18,581. Mesa Laboratories has a 1 year low of $117.58 and a 1 year high of $169.80. The company has a market cap of $516.93, a P/E ratio of -135.10 and a beta of 0.52. The company has a quick ratio of 1.64, a current ratio of 2.37 and a debt-to-equity ratio of 0.58.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Tuesday, February 27th. Mesa Laboratories’s payout ratio is currently -64.00%.
In related news, Director John Bradley Schmieder sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the director now directly owns 77,869 shares in the company, valued at approximately $10,299,732.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John James Sullivan sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $138.00, for a total transaction of $552,000.00. Following the sale, the director now owns 72,248 shares in the company, valued at $9,970,224. The disclosure for this sale can be found here. Corporate insiders own 15.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in the stock. DF Dent & Co. Inc. lifted its stake in shares of Mesa Laboratories by 3.8% during the 4th quarter. DF Dent & Co. Inc. now owns 10,932 shares of the medical instruments supplier’s stock valued at $1,359,000 after buying an additional 396 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Mesa Laboratories during the 4th quarter valued at approximately $183,000. Deutsche Bank AG lifted its stake in shares of Mesa Laboratories by 145.7% during the 4th quarter. Deutsche Bank AG now owns 7,140 shares of the medical instruments supplier’s stock valued at $886,000 after buying an additional 4,234 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in shares of Mesa Laboratories by 6.4% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 58,252 shares of the medical instruments supplier’s stock valued at $7,241,000 after buying an additional 3,486 shares in the last quarter. Finally, Sapphire Star Partners LP lifted its stake in shares of Mesa Laboratories by 207.0% during the 4th quarter. Sapphire Star Partners LP now owns 4,847 shares of the medical instruments supplier’s stock valued at $602,000 after buying an additional 3,268 shares in the last quarter. Institutional investors own 72.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/20/zacks-mesa-laboratories-inc-mlab-receives-average-rating-of-strong-buy-from-brokerages.html.
About Mesa Laboratories
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.